Dopamine agonist vs placebo
Any dopamine agonist showed no clear difference in dropouts compared with placebo (moderate certainty).
- RR 1.04 [0.94, 1.14]20 studies · 1656 participantsModerate
Any dopamine agonist showed no clear difference in dropouts compared with placebo (moderate certainty).
Any dopamine agonist showed no clear difference in adverse events as N of participants with at least one adverse event compared with placebo (moderate certainty).
Any dopamine agonist showed no clear difference in abstinence (objective) Participants abstinent at the end of… compared with placebo (low certainty).
Any dopamine agonist showed no clear difference in abstinence at compared with placebo (low certainty).
Amantidine showed no clear difference in dropouts compared with antidepressants (moderate certainty).
Amantidine showed no clear difference in adverse events as N of participants with at least one adverse event compared with antidepressants (low certainty).
Amantidine may leads to lower abstinence (objective) N of subjects abstinent at the end of the study compared with antidepressants (low certainty).
Amantadine showed no clear difference in dropouts compared with placebo (moderate certainty).
Amantadine showed no clear difference in adverse events as N of participants with at least one adverse event compared with placebo (moderate certainty).
Amantadine showed no clear difference in abstinence (objective) N of subjects abstinent at the end of the study compared with placebo (low certainty).